This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
While clinicalsupply is essential to any successful trial, autologous cell therapy trials occupy the far end of the spectrum regarding risk tolerance. While many market-approved cell therapies available today are autologous products, allogeneic interventions are growing more common.
The expansion forms part of Catalent’s ongoing global strategy to increase its ability to handle, store and manage advanced therapies for clinicalsupply, and follows investments at its facilities in Philadelphia, Singapore, and Shanghai, China, in specialized, ultra-low temperature storage capabilities. With sites in the U.S.,
Analyzing the benefits and challenges of implementing direct-to-patient services in the clinicalsupply chain to help meet patient requirements, improve supply chain efficiency and accelerate speed to market.
The benefits of developing a patient-centric clinicalsupply chain.
Add bookmark.
And importantly, breaks from treatment or treatment protocols can literally make or break trials. There is no room for a missed dose, a scheduled follow-up visit or opportunities to bring new clinical sites on board. can have a significant impact on manufacturing timelines and drug supply chains.
Based on its leading expertise in antibody, protein and peptide technologies, MorphoSys, together with its partners, has developed and contributed to the development of more than 100 product candidates, of which 27 are currently in clinical development. In July 2020, the U.S.
These restrictions and uncertainty around the duration, severity and geographic scope of the COVID-19 outbreak are projected to slow down the enrolment of patients due to re-prioritisation of hospital activities towards COVID-19 patients and away from clinical studies such as PARADIGME. Forward-looking statements.
The companies are exploring these advances through their newly created Pfizer Amazon Collaboration Team (PACT) initiative, which applies AWS capabilities in analytics, machine learning, compute, storage, security, and cloud data warehousing to Pfizer laboratory, clinical manufacturing and clinicalsupply chain efforts.
Sairiyo is advancing the clinical development of its lead drug candidate, Cepharanthine, a repurposed and reformulated naturally derived compound for the potential treatment of cancer, neurological, inflammatory and infectious diseases. The global esophageal cancer drugs market is estimated to grow by USD $1.5
Discover key qualities to look for to bring treatments to market faster and improve patient outcomes. Discover key qualities to look for to bring treatments to market faster and improve patient outcomes. Discover key qualities to look for to bring treatments to market faster and improve patient outcomes.
In todays clinical research landscape, it is both essential and challenging to accelerate clinical trials. Speeding up timelines reduces costs, maximizes ROI and ensures that patients receive the treatments they need without unnecessary delays. Delays in clinical trials can have significant financial consequences for sponsors.
We organize all of the trending information in your field so you don't have to. Join 15,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content